セリン/スレオニンプロテインキナーゼPim2（Pim2hまたは癌原遺伝子 Pim2またはPIM2またはEC2.7.11.1）のパイプライン標的は、約10つの分子で構成されており、そのうち、約10分子が企業によって開発されています。
セリン/スレオニンプロテインキナーゼPim2は、PIM2によってコードされる酵素で、細胞の生存と細胞増殖に関与しています。それは、ラパマイシン複合体1（mTORC1）に依存しない方法で、PI3K-Akt経路と並行して哺乳類の標的であるキャップ依存性タンパク質翻訳を調節します。これは、抗アポトーシスタンパク質Bcl-X（L）/ BCL2L1の放出を誘導するBADのリン酸化を介して生存シグナル伝達を仲介します。 I-カッパ-Bキナーゼ/NF-カッパ-Bカスケードの正の調節を介して、さまざまな増殖シグナルに応答して細胞の生存を促進します。
本レポートは、企業/大学によって開発されたセリン/スレオニンプロテインキナーゼPim2を標的とした治療薬に関する包括的な情報を、適応症、開発段階、作用機序（MoA）、投与経路（RoA）、分子タイプ別に分析したものです。
また、セリン/スレオニンプロテインキナーゼPim2を標的とした治療薬開発に関わる主要企業と、それぞれの活動中、休止中、中止のプロジェクトについてもレビューしています。現在、フェーズII、フェーズI、前臨床、創薬の各ステージで各社が開発している分子は、それぞれ1、1、6、2分子です。
本レポートでは、癌の治療領域に含まれる製品を対象としています。適応症には、血液腫瘍、急性骨髄細胞性白血病（AML、急性骨髄芽球性白血病）、骨髄線維症、急性リンパ球性白血病（ALL、急性リンパ芽球性白血病）、膀胱癌、乳癌、慢性リンパ球性白血病（CLL）、結腸癌、びまん性大細胞型B細胞リンパ腫 肝癌、肺癌、多発性骨髄腫（カーラー病）、骨髄異形成症候群、骨髄増殖性疾患、非小細胞肺癌、膵臓癌、汎発性血小板血症後骨髄線維症、多血性血小板血症後骨髄線維症（PPV-MF）、前立腺癌、難治性多発性骨髄腫、再発性多発性骨髄腫、固形腫瘍、およびトリプルネガティブ乳癌（TNBC）などが含まれます。
目次
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) - Overview
Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) - Companies Involved in Therapeutics Development
Amgen Inc
Incyte Corp
Inflection Biosciences Ltd
NewBay Medical Technology Co Ltd
Novartis AG
Sanofi
Sumitomo Dainippon Pharma Oncology, Inc
Yakult Honsha Co Ltd
Zovis Pharmaceuticals
Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) - Drug Profiles
GDC-0570 - Drug Profile
Product Description
Mechanism Of Action
History of Events
IBL-100 - Drug Profile
Product Description
Mechanism Of Action
History of Events
INCB-53914 - Drug Profile
Product Description
Mechanism Of Action
History of Events
JP-11646 - Drug Profile
Product Description
Mechanism Of Action
History of Events
LGB-321 - Drug Profile
Product Description
Mechanism Of Action
Small Molecule to Inhibit PIM1 and PIM2 for Hematological Tumors - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Inhibit PIM1, PIM2 and PIM3 for Solid Tumors and Hematological Tumors - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Inhibit PIM1 and PIM2 for Oncology - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit PIM2 for Oncology - Drug Profile
Product Description
Mechanism Of Action
TP-3654 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) - Dormant Products
Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) - Discontinued Products
Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) - Product Development Milestones
Featured News & Press Releases
Apr 10, 2021: Sumitomo Dainippon Pharma Oncology presents on TP-3654 at AACR Virtual Annual Meeting I 2021
May 29, 2020: Tolero Pharmaceuticals presents findings from first clinical studies evaluating investigational agent TP-3654 in patients with advanced solid tumors at ASCO Virtual Annual Meeting 2020
Apr 06, 2020: Boston Biomedical announces first patient dosed in phase 1 study of investigational agent TP-3654 in patients with myelofibrosis
May 14, 2019: Tolero Pharmaceuticals announces first patient dosed in phase 1 study of investigational agent TP-3654 in patients with advanced solid tumors
Oct 23, 2017: Tolero Pharma To Present Preclinical Data Supporting Development of Cancer Drug Candidate TP-3654 for Myc-dependent Triple Negative Breast Cancer
Oct 05, 2017: Tolero Pharma to Deliver Keynote Presentations at 9th International Conference on Leukemia and Hematologic Oncology
Jun 30, 2014: Tolero's PIM Kinase Inhibitor Demonstrates Promising Activity in Preclinical Models of Urothelial Carcinoma
Apr 04, 2014: Roswell Park to Present Findings on Jasco Pharmaceuticals' Novel PIM Inhibitor at AACR 2014
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products under Development by Indications, 2022 (Contd..1)
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by Amgen Inc, 2022
Pipeline by Incyte Corp, 2022
Pipeline by Inflection Biosciences Ltd, 2022
Pipeline by NewBay Medical Technology Co Ltd, 2022
Pipeline by Novartis AG, 2022
Pipeline by Sanofi, 2022
Pipeline by Sumitomo Dainippon Pharma Oncology, Inc, 2022
Pipeline by Yakult Honsha Co Ltd, 2022
Pipeline by Zovis Pharmaceuticals, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Discontinued Products, 2022
List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
